Warning: array_key_exists(): The first argument should be either a string or an integer in D:\Inetpub\webs\924517_web\www\lang_set.inc.php on line 7 Prof. MUDr. Cyril Höschl DrSc. FRCPsych.

Krátká sdělení v angličtině

  1. Höschl C.: Verapamil for depression ? Am. J. Psychiat., 140, 1983, 8: 1100.
  2. Höschl C., Stárka L., Roth Z., Jaššová J. et al.: Dexamethasone suppression test (DST) in psychiatric patients: multidimensional linear regression analysis. Activ.nerv.sup.,26, 1984, 1: 43-44.
  3. Höschl C., Stárka L., Ornstová J. et al.: Reproducibility of the Dexamethasone suppression test in psychiatric patients. Activ.nerv.sup.,26,1984, 1: 44-45.
  4. Höschl C., Roth Z.: Thyreoliberin-test in psychiatric patients: multidimensional linear regression analysis. Activ.nerv.sup.,26, 1984, 1: 48-50.
  5. Bakeš K., Zárubová V., Höschl C., Blahoš J.: Are the effects of neuroleptics on glycide metabolism due to the influence of calcium and calmodulin? Activ. nerv. sup., 27, 1985, 1: 47-48.
  6. Höschl C., Blahoš J., Kabeš J., Hessler M.: Therapeutic use of verapamil in affective disorders. Activ. nerv. sup., 27, 1985, 1: 60-61.
  7. Höschl C., Karásková E., Kožený J., Stárka,L.: Dexamethasone suppression test in alcohol addicts. Activ. nerv.sup.,27, 1985, 4: 277-278.
  8. Höschl C., Blahoš J., Kabeš J., Hessler M.: Experience with verapamil in psychiatry. Activ.nerv.sup.,27,1985, 4: 253-255.
  9. Žantovský M., Höschl C., Nešporová B., Hendrychová Y.: Dominance hierarchy, initiation of interaction and estimates of present state in psychiatric inpatients. Activ. nerv. sup.,31, 1989, 2: 89-92.
  10. David I., Höschl C., Filip V., Karen P.: The effect of levoprotiline and maprotiline single dose on C-EEG during 24 hours. Homeostasis, 34, 1993, 3-4:212-213
  11. Höschl C.: Challenges in Developing Models for Psychiatric Education in Eastern Europe. World Psychiatry, 2, 1994, 5: 5-8.
  12. Řípová D., Němcová V., Strunecká A., Höschl C.: Inositol lipid signalling system in schizophrenia. Homeostasis, 36 (suppl.1), 1995: 126.
  13. Höschl C., Sartorius N., Mohr P.: Comparison of Undergraduate and Postgraduate Psychiatric Training in Eastern Europe. Europ. Neuropsychopharmacol., 6, 1996, Suppl. 3: 14.
  14. Řípová D., Němcová V, Höschl C., Strunecká A.: Age-dependent changes in the lipid composition of rat brain cortex and cerebellum. Homeostasis, 38, 1997, No 1, p. 31-33.
  15. Balon R., Höschl C.: Commentary on National Trends in behavioral sciences (1981-1996). Psychotherapy and Psychosomatics, 1998; 67:288-289.
  16. Kopeček M., Höschl C., Hájek T.: Regional selectivity of novel antipsychotics. Brit. J. Psychiatry 2002, 181:254-255.
  17. Sokol J., Štulík K., Höschl C.: Laudatio: Zdeněk Klein. Neuroendocrinology Letters Special Issue, 23, 2002, Suppl. 4:8-9.
  18. Höschl C.: What is the role of cerebellum in regulating cognitive functions in psychotic patients? In: Driss Moussaoui (ed.), Unanswered questions in psychiatry and mental health. WPA, 2002, p 34.
  19. Höschl C.: Are there new treatment possibilities to prevent neuronal death? In: Driss Moussaoui (ed.), Unanswered questions in psychiatry and mental health. WPA, 2002, pp 59-60.
  20. Kopeček M., Höschl C. Hájek T. Selectivity of atypical antipsychotic. Br. J. Psychatr. 9:2002,534-535.
  21. Höschl C.: Neuropsychopharmacology in the Czech Republic. ECNP matters, issue 5, June 2003, p. 1.
  22. Šťastný F, Tejkalová H, Höschl C, Balcar VJ. Viral infection, glutamatergic deficit and behavioral changes in animal model of schizophrenia. Psychiatrie 2003;7(Suppl.2):128-130.
  23. Höschl C.: 16th ECNP congress in Prague, Czech reflections. (Prof. Höschl, local adviser 16th ECNP Congress). ECNP Matters, Newsletter, No. 6, December 2003, p. 4.
  24. Höschl C.: Editorial. AEP Newsletter, 8, Summer 2007, p. 1.
  25. Results of the meta-analysis may also depend on outcome measures. Letter. PLoS, 28 Feb 2008
  26. Höschl C.: Editorial. AEP Newsletter, 9, Winter 2007/2008, p. 1.
  27. Höschl C.: Editorial (European perspectives in psychiatry: antidepressants as an example). Acta Psychiatr Scand 2008; 118:89-90.
  28. Höschl C., Stopková P. Discrete and continuous approaches in the conceptualization of schizophrenia and bipolar disorder. Engrami,30,2008;2(S1):151-154.ISSN: 0351-2665
  29. Höschl C.: Editorial. EPA Newsletter, 10, Summer/Autumn 2008, p. 1.
  30. Höschl C.: Editorial. EPA Newsletter, 11, Winter 2008, p. 1.
  31. Höschl C, Stopková P. Schizophrenia update: Discrete and continuous approach in the conceptualization of schizophrenia and bipolar disorder. Proceedings of 2009 ECNP-EPA Seminar in Neuropsychopharmacology, 28-30.5.2009, Czernijewo, Polsko, str.36-53. ISBN 978-83-7597-039-5
  32. Grunze HC, Höschl C, Montgomery SA, Sartorius N, Vieta E. Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. J Clin Psychopharmacol. 2009;29(4):409
  33. Höschl C. Recommended guidance beyond guidelines. Annals Gen Psychiatry, 2010;9 (suppl. 1):S44
  34. Höschl C.: Concluding remarks. European Psychiatry, 25; 2010, Suppl 2: S46
  35. Höschl C.: Importance of physical health in patients with schizophrenia. European Psychiatry, 25; 2010, Suppl 2: S1-S2.
  36. Horacek J, Flegr J, Tintera J, Novak T, Brunovsky M, Bubenikova-Valesova V, Palenicek T, Höschl C. Latent Toxoplasmosis Reduces Gray Matter Density in Schizophrenia but not in Controls. Voxel-Based-Morphometry (VBM) Study. Poster, 49th Annual Meeting of American College of Neuropsychopharmacology, Miami, FL, USA December 5-9, 2010
  37. Höschl C.: Report of FEAM activities in 2010. Czech Medical Academy Review. 7, 2011:42.
  38. Höschl C.: BEDŘICH SMETANA - ART AND DISEASE. Psychiatria Danubina, 2012; Vol. 24, Suppl. l, pp 176-178.
  39. Stein D, Khoo JP, Van Ameringen M, Hoschl C, et al. Efficacy and safety of Agomelatine (25-50 Mg/Day) versus Escitalopram (10-20 Mg/Day) in severe Generalized Anxiety Disorder. Australian and New Zealand Journal of Psychiatry 52, Apr 2018; S1: 136-137
  40. van Erp TGM, Walton E, Hibar DP, …, Hoschl C, …, Turner JA. Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process? Biological Psychiatry April 1, 2019; 85:e35–e39; doi: 10.1016/j.biopsych.2018.10.003.
  41. Höschl C. Introduction: An overview of NIMH (Klecany, CZ) scientific activities. Neuroscience Letters, 2021 (749) xxx https://doi.org/10.1016/j.neulet.2021.135790
  42. Congratulations on the 90th birthday of Prof. Stanislav Grof.